February 9, 2012
Agios Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
January 3, 2012
Agios Pharmaceuticals to Present at 30th Annual J.P. Morgan Healthcare Conference
November 17, 2011
Agios Secures $78 Million in Oversubscribed Series C Financing
November 1, 2011
Celebrating 16 Years of Cancer Support at Gilda’s Club NYC
October 5, 2011
Celgene and Agios Extend Cancer Metabolism Collaboration
September 20, 2011
Marc Tessier-Lavigne, Ph.D., President of The Rockefeller University, Joins Agios Board of Directors
August 2, 2011
Agios Founder and Advisor Publish In Nature Genetics On Further Links Between Serine Metabolic Pathway and Cancer
July 14, 2011
Agios and Whitehead Institute Collaborate on Nature Publication Revealing Altered Metabolic Pathway in Breast Cancer
March 1, 2011
Agios Pharmaceuticals to Present at 31st Annual Cowen Healthcare Conference
January 6, 2011
Agios Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
December 14, 2010
Agios Announces Cancer Cell Publication of Research Illuminating Link between Cancer Metabolism and Epigenetics
November 4, 2010
Agios Awarded Two Federal Grants to Advance Cancer Metabolism Focused Therapeutics
September 20, 2010
Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
July 29, 2010
Agios Creates Expanded Scientific Advisory Role for Lewis Cantley, Ph.D.
June 24, 2010
Agios Appoints John Maraganore, Ph.D., to Board of Directors
April 21, 2010
Agios Scientists Present IDH1 Data at 2010 AACR Meeting
April 15, 2010
Celgene Corporation and Agios Pharmaceuticals Announce Global Strategic Collaboration to Advance Unique Science of Cancer Metabolism
March 11, 2010
Agios Pharmaceuticals Appoints William Kaelin Jr., M.D., to Scientific Advisory Board
December 21, 2009
Agios Pharmaceuticals Awarded Funding From Accelerate Brain Cancer Cure (ABC2) to Support Research into Novel Therapeutics and Diagnostics for Brain Cancer
November 23, 2009
Agios Publishes Groundbreaking Research in Nature Uncovering the New Role of IDH1 Gene Mutation in Brain Cancer
June 29, 2009
FierceBiotech Names Agios Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2009
May 28, 2009
Agios Pharmaceuticals' Focus of Drug Research - Cancer Metabolism - Selected for Stand Up To Cancer Grant
May 27, 2009
Agios Pharmaceuticals Appoints David Schenkein, M.D., as CEO and Duncan Higgons as COO
April 30, 2009
Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR
February 6, 2009
Agios Pharmaceuticals Appoints Charles Sawyers, M.D.,to Scientific Advisory Board
November 24, 2008
Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team
November 24, 2008
Agios Pharmaceuticals Expands Into 21,000 SqFt Facility
July 7, 2008
Agios Pharmaceuticals Closes $33 Million Series A Funding